A CACNA1D mutation in a patient with persistent hyperinsulinaemic hypoglycaemia, heart defects, and severe hypotonia
S E Flanagan1, F Vairo2, M B Johnson1
1Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
Insights
Genetic analysis identified a CACNA1D gene mutation in a child with congenital hyperinsulinaemic hypoglycaemia (HH). This finding confirms CACNA1D
Area of Science:
- Endocrinology
- Genetics
- Molecular Biology
Background:
- Congenital hyperinsulinaemic hypoglycaemia (HH) is a rare disorder of glucose regulation.
- Genetic mutations cause 50%-60% of HH cases, necessitating genetic diagnosis for management and recurrence risk assessment.
- CACNA1D encodes a key calcium channel in pancreatic beta cells, crucial for insulin secretion.
Observation:
- Exome sequencing of a patient with diazoxide-responsive HH, hypotonia, and developmental delay revealed a de novo CACNA1D mutation (p.G403D).
- This activating mutation was previously linked to primary hyperaldosteronism and neuromuscular issues.
- Further analysis of 60 HH cases did not reveal additional CACNA1D mutations.
Findings:
- A de novo activating mutation in CACNA1D was identified in a patient with congenital hyperinsulinaemic hypoglycaemia.
- This confirms CACNA1D as a causative gene for HH.
- The identified mutation impacts L-type calcium channel function in pancreatic beta cells.
Implications:
- Genetic diagnosis of HH is crucial for informing recurrence risk and guiding treatment.
- CACNA1D mutations are confirmed as a cause of congenital hyperinsulinaemic hypoglycaemia.
- Calcium channel blockers may represent a potential therapeutic option for patients with CACNA1D-related HH.
Abstract:
Congenital hyperinsulinaemic hypoglycaemia (HH) can occur in isolation or it may present as part of a wider syndrome. For approximately 40%-50% of individuals with this condition, sequence analysis of the known HH genes identifies a causative mutation. Identifying the underlying genetic aetiology in the remaining cases is important as a genetic diagnosis will inform on recurrence risk, may guide medical management and will provide valuable insights into β-cell physiology. We sequenced the exome of a child with persistent diazoxide-responsive HH, mild aortic insufficiency, severe hypotonia, and developmental delay as well as the unaffected parents. This analysis identified a de novo mutation, p.G403D, in the proband's CACNA1D gene. CACNA1D encodes the main L-type voltage-gated calcium channel in the pancreatic β-cell, a key component of the insulin secretion pathway. The p.G403D mutation had been reported previously as an activating mutation in an individual with primary hyper-aldosteronism, neuromuscular abnormalities, and transient hypoglycaemia. Sequence analysis of the CACNA1D gene in 60 further cases with HH did not identify a pathogenic mutation. Identification of an activating CACNA1D mutation in a second patient with congenital HH confirms the aetiological role of CACNA1D mutations in this disorder. A genetic diagnosis is important as treatment with a calcium channel blocker may be an option for the medical management of this patient.
Related Concept Videos
Inborn Errors of Metabolism
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Hypoglycemia and Glucagon


